Beyond anaemia management: evolving role of erythropoietin therapy in neurological disorders, multiple myeloma and tumour hypoxia models.

@article{Boogaerts2005BeyondAM,
  title={Beyond anaemia management: evolving role of erythropoietin therapy in neurological disorders, multiple myeloma and tumour hypoxia models.},
  author={Marc A. Boogaerts and Moshe Mittelman and Peter Vaupel},
  journal={Oncology},
  year={2005},
  volume={69 Suppl 2},
  pages={
          22-30
        }
}
Recombinant human erythropoietin (epoetin) has become the standard of care in the treatment of anaemia resulting from cancer and its treatment, and chronic kidney disease. The discovery that erythropoietin and its receptor are located in regions outside the erythropoietic system has led to interest in the potential role of epoetin in other tissues, such as the central nervous system. Animal studies have shown that systemically applied epoetin can cross the blood-brain barrier, where it reduces… CONTINUE READING

Citations

Publications citing this paper.

References

Publications referenced by this paper.
SHOWING 1-10 OF 62 REFERENCES

Erythropoietin and erythropoietin receptor expression in head and neck cancer: relationship to tumor hypoxia.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2005

Expression of erythropoietin and erythropoietin receptor in non-small cell lung carcinomas.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2005

Effect of epoetin beta on tumour progression and survival in patients with cancer: a meta-analysis of controlled clinical studies

M Aapro, J Dunst, +3 authors HU Burger
  • Ann Oncol
  • 2004